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dverse effects of pharmacotherapeutics in patients rarely
ead to novel therapies in animal models of disease. In this
ssue of the Journal, however, Liu et al. (1) provide a
emarkable case of such “bedside-to-bench” research: they
emonstrate that neuregulin-1 therapy substantially miti-
ates heart failure in infarct-, viral-, anthracycline-,
nd pacing-induced models that employ rodents and dogs—
xperimental proofs of concept critical for launching human
tudies. The discovery by Liu et al. (1) derived, in part, from
he observation that trastuzumab (Herceptin) therapy for
reast cancer engenders cardiomyopathy (2). Why does
See page 1438
yocardial function deteriorate consequent to treatment
ith this monoclonal antibody, which targets a receptor
yrosine kinase (RTK) called “neu”—an antibody that re-
uces expression of and therefore intracellular signaling by
eu (also known as ErbB2 or HER2)? And why might we
xpect myocardial function to resist deterioration, or de-
ressed myocardial function to improve, in response to an
gent that activates neu (a “neuregulin”)?
he ErbB family of RTKs. Receptor tyrosine kinases are
ell surface proteins that regulate many essential cell type-
pecific functions, particularly cell growth, proliferation, and
urvival (Fig. 1). The ErbB family of RTKs includes 4
istinct receptors (ErbB1 to ErbB4), each of which shares
equence similarity with a protein encoded by the chicken
etroviral oncogene v-erbB (for which this RTK family is
amed). ErbB2 was originally named “neu” because it was
iscovered in its oncogene form in rat neuroblastoma cells
3). In homage to history and the importance of ErbB2 in
eural tissue, we refer to an important group of proteins that
timulate ErbB2 as the neuregulins. Neuregulins selectively
romote heterodimerization between a monomer of ErbB2
nd a monomer of either ErbB4 or ErbB3 (4), and appear
o be critically important for normal cardiovascular function.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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orth Carolina.rbBs and cardiac function. Although ErbB2 and ErbB4
re expressed on the surface of cardiomyocytes, neuregulin-1 is
eleased from the surface of endocardial and microvascular
ndothelial cells (5). In this way, neuregulin-1 is believed to
xert a paracrine influence on cardiomyocytes. Genetic
eficiency of ErbB2, ErbB4, or neuregulin-1 in mice yields
remarkably congruent phenotype involving a failure of the
ardiac ventricle to undergo trabeculation (4). Correlation
etween depressed myocardial function and depressed myo-
ardial ErbB levels can be made in both adult rodents
6) and human subjects (7). Moreover, recovery of myocar-
ial dysfunction with effective heart failure treatment has
een correlated with recovery of myocardial ErbB levels (7).
causal relationship between ErbB2 deficiency and heart
ailure can be seen in mice with myocardium-specific gene
argeting that reduces myocardial ErbB2 expression by
70%: hearts that develop normally nonetheless develop a
ilated cardiomyopathy that mimics human dilated cardio-
yopathy in a number of ways (8). Lastly, when trastu-
umab is used in breast cancer therapy to reduce ErbB2
ignaling, left ventricular dysfunction develops in 13% to
8% of patients, depending on the relative timing of
rastuzumab and anthracycline chemotherapy (2). Collec-
ively, these previous data demonstrate that impairing
rbB2 signaling impairs myocardial function. Now we have
vidence that the converse is also true: augmenting ErbB2
ignaling can improve myocardial function (1).
rbB signaling reduces cardiomyocyte apoptosis. There
s evidence supporting a role for cardiomyocyte apoptosis, or
programmed cell death,” in human heart failure and
ardiomyopathy (9). By reducing the number of viable
ardiomyocytes, apoptosis perpetuates a vicious cycle: 2
yocardial function¡ 1myocyte mechanical stretch,
neurohumoral activation¡1cardiomyocyte dysfunction,
apoptosis¡ 2myocardial function. Neuregulin-1 ther-
py can interrupt this vicious circle (1), quite plausibly by
educing cardiomyocyte apoptosis. Neuregulin-1 promotes
ypertrophy and proliferation of adult and embryonic
ardiomyocytes, respectively, through activation of
rbB2 and ErbB4, and simultaneously protects cardio-
yocytes from apoptosis (5). Conversely, reduction of
rbB2 signaling appears to augment cardiomyocyte apo-
tosis: in vivo, the 70% reduction in cardiomyocyte
rbB2 expression that engenders heart failure in mice
lso substantially increases apoptosis in cardiomyocytes
8). Moreover, gene therapy with an anti-apoptotic
rotein ameliorated the heart failure phenotype in these
ice (8).
How can signaling initiated by ErbB2 and ErbB4 protect
ardiomyocytes from apoptosis? Cardiomyocyte anti-
poptotic ErbB signaling involves activation of at least one
ther (serine/threonine) kinase, Akt (10,11). Gene deletion
tudies in mice have demonstrated that a specific Akt
soform is critical for cardiac development, and that Akt
revents apoptosis in vivo (12). Moreover, when ErbB-
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October 3, 2006:1448–50 Editorial Commentediated cardiomyocyte Akt activation is inhibited, the
nti-apoptotic activity of neuregulin-1 is abrogated (11). It
s believed that Akt attenuates apoptosis by phosphorylating
and thereby inactivating) a variety of proteins that mediate
mportant steps in the choreography of programmed cell
eath (9).
Although activation of cardiomyocyte Akt by cell surface
eceptors may be necessary to protect cardiomyocytes from
poptosis, it is clearly not sufficient. Angiotensin II, for
xample, activates cardiomyocyte Akt and engenders cardi-
myocyte hypertrophy but also promotes cardiomyocyte
poptosis (13). Thus, it seems likely that the net effect of
yriad variables—including the degree of Akt activation
nd concurrent activation of other cardiomyocyte signaling
athways—determine whether a stimulus will result in
ardiomyocyte survival or apoptosis. Other agonists that
ppear to promote a favorable anti-apoptotic balance be-
ween Akt and other cardiomyocyte signaling include
nsulin-like growth factor-1 (which stimulates its own
TK) (14) and cardiotrophin-1 (which stimulates cytokine
eceptors that signal through non-RTKs) (15). In neither of
hese cases, however, do we have therapeutic data compa-
able to those provided by Liu et al. (1) for neuregulin-1.
rom bench to bedside—again. Like many seminal stud-
es, the work of Liu et al. (1) raises a plethora of questions.
hat will be the therapeutic index for neuregulin-1 in
uman subjects, given its potential for pleiotropic effects
nvolving the other cell types that express ErbB2, ErbB3,
nd ErbB4 (skeletal muscle, neuronal, glial, and epithelial)?
nlike receptor antagonists, whose effects are fairly stable
ver time, receptor agonists engender desensitization of
ignaling pathways with prolonged use (16). Will tachyphy-
axis complicate, or even vitiate, long-term therapy with
igure 1. Schematic for ErbB action in cardiomyocytes. Neuregulin-1 (NR
rbB4 (R4) and its co-receptor ErbB2 (R2). ErbB2 and ErbB4 phosphoryla
ites for multiple signal transduction proteins (shaded gray/blue). Subse
PI3K], at left) initiates multiple signaling cascades, including those invol
poptotic signaling and promotes cellular hypertrophy, ERK phosphorylateuregulins in human subjects? Liu et al. (1) have carefullyoted that dosing of neuregulin-1 therapy is critical for its
afety and efficacy in heart failure, even in mice. What
iming and frequency of administration will be optimal for
euregulin-1 efficacy in patients? We have witnessed spec-
acular success in breast cancer (17) and chronic myeloid
eukemia (18) patients treated with antagonist or inhibitor
herapies, respectively, targeting the ErbB2 tyrosine kinase
r the BCR-ABL tyrosine kinase. Will the pro-neoplastic
otential of prolonged agonist therapies involving RTKs be
n insuperable barrier to therapeutic use of neuregulin-1? By
nalogy to the use of anti-ErbB2 therapy for only breast
denocarcinomas with ErbB2 overexpression, will
euregulin-1 therapy for heart failure be a targeted therapy
or patients with the lowest levels of myocardial ErbB
xpression? In addressing these and other questions, the
ench-to-bedside odyssey of neuregulin-1 heart failure
herapy should productively occupy us for many years to
ome.
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